Portfolio Vendor Leader

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

76Bio

8Biomed

A-Alpha Bio

A2 Biotherapeutics

AavantiBio

Ab Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

ACELYRIN

Acepodia

Achieve Life Sciences

Acrivon Therapeutics

Acutis Diagnostics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Aditum Bio

adMare BioInnovations

Admera Health

Adverum Biotechnologies

adyn

Aeglea BioTherapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

Affinivax

AgBiome

Agena Bioscience

AIRNA Bio

Akero Therapeutics

Akouos

Alamar Biosciences

Alector

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allakos

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

Alltrna

AlpaLifeBio

Alpha-9 Theranostics

Alphabioregen

Alpine Immune Sciences

Altis Biosystems

Alto Neuroscience

AltPep

Alumis

Alveo Technologies

Alveolus Bio

ALX Oncology

Alzheon

AmbAgon Therapeutics

Amberstone Biosciences

Amolyt Pharma

Amylyx Pharmaceuticals

AN2 Therapeutics

Anagram Therapeutics

Andes

Angiex

Angiocrine Bioscience

AnHeart Therapeutics

Annexon Biosciences

Anokion

Ansa Biotechnologies

Antheia

Anthos Therapeutics

AOA Dx

Apic Bio

Apollomics

Appia Bio

Applied Molecular Transport

Apriori Bio

Aptevo Therapeutics

Apton Biosystems

Aptose Biosciences

Aquinnah Pharmaceuticals

Aramis Biosciences

Arbor Biotechnologies

Arcadia Science

Arcellx

Arctoris

Arcturus Therapeutics

Arcutis Biotherapeutics

Arima Genomics

Ark Biotech

Caribou Biosciences is developing CRISPR technologies to create allogeneic cell therapies for oncology. Caribou has built CRISPR hybrid RNA-DNA (chRDNA), their proprietary technology that enables highly efficient, highly specific genome editing. chRDNA is then used to develop sophisticated genome-edited cell therapies. For example, Caribou is using chRDNA to create next-generation allogeneic CAR-T and CAR-NK cell therapies to enhance the longevity and persistence of the cells. Scientific advances have been published in high-impact journals. Caribou has one ongoing Phase I clinical trial to evaluate CB-010 in adults with relapsed B cell non-Hodgkin lymphoma.

<p>Caribou Biosciences is developing CRISPR technologies to create allogeneic cell therapies for oncology. Caribou has built CRISPR hybrid RNA-DNA (chRDNA), their proprietary technology that enables highly efficient, highly specific genome editing. chRDNA is then used to develop sophisticated genome-edited cell therapies. For example, Caribou is using chRDNA to create next-generation allogeneic CAR-T and CAR-NK cell therapies to enhance the longevity and persistence of the cells. Scientific advances have been published in high-impact journals. Caribou has one ongoing Phase I clinical trial to evaluate CB-010 in adults with relapsed B cell non-Hodgkin lymphoma.</p>


Find a biotech startup job.